Neurotransmitter release in experimental stroke models: the role of glutamate-GABA interaction.
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001921:Brain / Q000033:anatomy & histology / Q000166:cytology / Q000503:physiopathology; D026603:D-Aspartic Acid / Q000378:metabolism; D004195:Disease Models, Animal; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology; D066298:In Vitro Techniques; D020244:Infarction, Middle Cerebral Artery / Q000378:metabolism / Q000503:physiopathology; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D020521:Stroke / Q000378:metabolism*; D013778:Tetrazolium Salts / Q000378:metabolism; D014316:Tritium / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D018691:Excitatory Amino Acid Antagonists; D013778:Tetrazolium Salts; D014316:Tritium; D018698:Glutamic Acid; D026603:D-Aspartic Acid; D005680:gamma-Aminobutyric Acid; C009591:triphenyltetrazolium